Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

NCT01232881 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.

NCT NCT01232881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01232881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
Lead sponsor
Hoosier Cancer Research Network
Phase
Observational
Overall status
Terminated
Start date
August 31, 2009
Completion date
November 30, 2010
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer